ReviewInflammopharmacology2018
IL-6 signalling pathways and the development of type 2 diabetes.
Review in Inflammopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 9 syntheses or guidelines pooled it, 297 citations in OpenAlex.
- Epigenome-wide association study of circulating interleukin-6 connects DNA methylation to immunometabolic and inflammatory health.Communications biology · 2026Pooled it
- Effect of Quercetin on inflammatory markers in diabetes mellitus: a systematic review and meta-analysis of animal studies.Inflammopharmacology · 2026Pooled it
- Revisiting the markers interleukin-6 and glucagon-like peptide-1 for targeting low-grade inflammation in type 2 diabetes: a meta-analysis and our lab experience.Acta diabetologica · 2025Pooled it
- Pooled it
- Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes.European journal of clinical pharmacology · 2023Pooled it
- Interleukin-6 levels can be used to estimate cardiovascular and all-cause mortality risk in dialysis patients: A meta-analysis and a systematic review.Immunity, inflammation and disease · 2023Pooled it
- The Promising Role of Microbiome Therapy on Biomarkers of Inflammation and Oxidative Stress in Type 2 Diabetes: A Systematic and Narrative Review.Frontiers in nutrition · 2022Pooled it
- Meta-analysis: Interleukin 6 gene -174G/C polymorphism associated with type 2 diabetes mellitus and interleukin 6 changes.Journal of cellular and molecular medicine · 2021Pooled it
- The association of interieukin-6 polymorphism (rs1800795) with microvascular complications in Type 2 diabetes mellitus.Bioscience reports · 2020Pooled it
- Effects of a Circuit Training Program on Myokine Levels in Insulin-Resistant Women: A Randomised Controlled Trial.Journal of diabetes research · 2024Trial
- Marginal Impact of Brown SeaweedMarine drugs · 2022Trial
- Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, andFrontiers in endocrinology · 2022Trial
- Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.Arthritis research & therapy · 2020Trial
- A Retrospective Analysis of the Association Between Prediabetes and Biomarkers of Intestinal Permeability in Patients with Prediabetes from Durban, South Africa.International journal of molecular sciences · 2026Article
- Article
- Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.Global cardiology science & practice · 2026Review
- Association of Triglyceride-Glucose Index With In-Hospital Malignant Arrhythmias in Older Patients With Diabetes Mellitus and Left Ventricular Aneurysm: A Retrospective Study.Reviews in cardiovascular medicine · 2026Article
- Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.Endocrinology, diabetes & metabolism · 2026Article
- Muscle and Liver Insulin Resistance Are Associated with Distinct Plasma Protein Profiles: Data from the DiOGenes Trial.The Journal of clinical endocrinology and metabolism · 2026Article
- Unraveling the Systems Biology of Curcumin: A Mini-review of its Anti-diabetic Potential through Network Pharmacology.Cell biochemistry and biophysics · 2026Review
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin 6 (IL-6), a multifunctional cytokine, has been implicated in the pathophysiology of type 2 diabetes (T2D). The elevated circulating level of IL-6 is an independent predictor of T2D and is considered to be involved in the development of inflammation, insulin resistance and β-cell dysfunction. On the other hand, an increasing number of evidence suggests that IL-6 has an anti-inflammatory role and improves glucose metabolism. The complex signal transduction mechanism of IL-6 may help explain the pleiotropic nature of the cytokine. IL-6 acts via two distinct signalling pathways called classic signalling and trans-signalling. While both signalling modes lead to activation of the same receptor subunit, their final biological effects are completely different. The aim of this review is to summarize our current knowledge about the role of IL-6 in the development of T2D. We will also discuss the importance of specific blockade of IL-6 trans-signalling rather than inhibiting both signalling pathways as a therapeutic strategy for the treatment of T2D and its associated macrovascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.